Two medications for high blood pressure in the liver
Part of Digestive system clinical trials.
This study tests whether adding alverine to carvedilol helps lower pressure in the liver's blood vessels in people with cirrhosis, which may reduce the risk of bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with cirrhosis of the liver.
- You have been taking carvedilol for at least 3 months, and your liver pressure is still high.
- You haven't had certain procedures or treatments for liver pressure recently.
- You are not currently pregnant or breastfeeding.
- You do not have certain other serious health conditions or infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies alverine to lower portal hypertension, which is high blood pressure in the liver that can happen with cirrhosis. If it works safely, it may reduce pressure-related complications in people with confirmed liver scarring.
This trial tests whether a medicine called carvedilol can lower high blood pressure in the liver veins of people with cirrhosis. It uses a special ultrasound probe to measure the pressure before and after taking the medicine.
This trial tests whether a long-term medicine called carvedilol can prevent liver failure or death in people with early-stage cirrhosis and high pressure in the liver's blood vessels. It may help delay serious complications and improve outcomes.
This trial tests whether adding metformin to carvedilol (a standard drug) lowers liver pressure more than carvedilol alone in people with cirrhosis who have had variceal bleeding. The goal is to prevent future bleeding.
This study tests whether adding a second drug (midodrine) to the standard drug (carvedilol) is better at preventing another bleeding episode from varices in people with cirrhosis. It aims to reduce the risk of early re-bleeding and improve outcomes.
This study tests a medicine called carvedilol (a non-selective beta-blocker) to see if it can prevent complications in people with advanced chronic liver disease who are at high risk but haven't had serious problems like bleeding yet.
Hear when a new Hypertension, Portal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.